These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 26873482)

  • 21. Quantitative Measurement of the Direct Public Health Impact of Medicines Withdrawals in Europe: Development of a Modelling Method and Proof-of-Concept Study to Estimate the Morbidity and Mortality Prevented by Regulatory Action.
    Lane S; Lynn E; Shakir S
    Pharmacoepidemiol Drug Saf; 2024 Sep; 33(9):e70003. PubMed ID: 39212104
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Direct reporting by patients of adverse drug reactions in Spain].
    Esther Salgueiro M; Jimeno FJ; Aguirre C; García M; Ordóñez L; Manso G
    Farm Hosp; 2013; 37(1):65-71. PubMed ID: 23461502
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regulatory anticipation of postmarket safety problems for novel medicines approved by the EMA between 2001 and 2010: a cross-sectional study.
    Zeitoun JD; Lefèvre JH; Downing NS; Bergeron H; Ross JS
    Pharmacoepidemiol Drug Saf; 2016 Jun; 25(6):687-94. PubMed ID: 26554874
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An Empirical Approach to Explore the Relationship Between Measures of Disproportionate Reporting and Relative Risks from Analytical Studies.
    Maciá-Martínez MA; de Abajo FJ; Roberts G; Slattery J; Thakrar B; Wisniewski AF
    Drug Saf; 2016 Jan; 39(1):29-43. PubMed ID: 26507885
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Contribution of National Spontaneous Reporting Systems to Detect Signals of Torsadogenicity: Issues Emerging from the ARITMO Project.
    Raschi E; Poluzzi E; Salvo F; Koci A; Suling M; Antoniazzi S; Perina L; Hazell L; Moretti U; Sturkenboom M; Garbe E; Pariente A; De Ponti F
    Drug Saf; 2016 Jan; 39(1):59-68. PubMed ID: 26446144
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Post-marketing withdrawal of analgesic medications because of adverse drug reactions: a systematic review.
    Onakpoya IJ; Heneghan CJ; Aronson JK
    Expert Opin Drug Saf; 2018 Jan; 17(1):63-72. PubMed ID: 29076385
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of healthcare databases and registries for surveillance of orphan drugs in the real-world setting: the Italian case study.
    Crisafulli S; Sultana J; Ingrasciotta Y; Addis A; Cananzi P; Cavagna L; Conter V; D'Angelo G; Ferrajolo C; Mantovani L; Pastorello M; Scondotto S; Trifirò G
    Expert Opin Drug Saf; 2019 Jun; 18(6):497-509. PubMed ID: 31059293
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug withdrawals in the United States: a systematic review of the evidence and analysis of trends.
    Issa AM; Phillips KA; Van Bebber S; Nidamarthy HG; Lasser KE; Haas JS; Alldredge BK; Wachter RM; Bates DW
    Curr Drug Saf; 2007 Sep; 2(3):177-85. PubMed ID: 18690965
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Can Disproportionality Analysis of Post-marketing Case Reports be Used for Comparison of Drug Safety Profiles?
    Michel C; Scosyrev E; Petrin M; Schmouder R
    Clin Drug Investig; 2017 May; 37(5):415-422. PubMed ID: 28224371
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Era of faster FDA drug approval has also seen increased black-box warnings and market withdrawals.
    Frank C; Himmelstein DU; Woolhandler S; Bor DH; Wolfe SM; Heymann O; Zallman L; Lasser KE
    Health Aff (Millwood); 2014 Aug; 33(8):1453-9. PubMed ID: 25092848
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Worldwide withdrawal of medicinal products because of adverse drug reactions: a systematic review and analysis.
    Onakpoya IJ; Heneghan CJ; Aronson JK
    Crit Rev Toxicol; 2016 Jul; 46(6):477-89. PubMed ID: 26941185
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pediatric post-marketing safety systems in North America: assessment of the current status.
    McMahon AW; Wharton GT; Bonnel R; DeCelle M; Swank K; Testoni D; Cope JU; Smith PB; Wu E; Murphy MD
    Pharmacoepidemiol Drug Saf; 2015 Aug; 24(8):785-92. PubMed ID: 26098297
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Postmarket safety in Canada: are significant therapeutic advances and biologics less safe than other drugs? A cohort study.
    Lexchin J
    BMJ Open; 2014 Feb; 4(2):e004289. PubMed ID: 24549164
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Signal Detection of Imipenem Compared to Other Drugs from Korea Adverse Event Reporting System Database.
    Park K; Soukavong M; Kim J; Kwon KE; Jin XM; Lee J; Yang BR; Park BJ
    Yonsei Med J; 2017 May; 58(3):564-569. PubMed ID: 28332362
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Considerations for the analysis of longitudinal electronic health records linked to claims data to study the effectiveness and safety of drugs.
    Lin KJ; Schneeweiss S
    Clin Pharmacol Ther; 2016 Aug; 100(2):147-59. PubMed ID: 26916672
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reported time to onset of neurological adverse drug reactions among different age and gender groups using metoclopramide: an analysis of the global database Vigibase®.
    Svendsen K; Wood M; Olsson E; Nordeng H
    Eur J Clin Pharmacol; 2018 May; 74(5):627-636. PubMed ID: 29290074
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Nordic prescription databases as a resource for pharmacoepidemiological research--a literature review.
    Wettermark B; Zoëga H; Furu K; Korhonen M; Hallas J; Nørgaard M; Almarsdottir A; Andersen M; Andersson Sundell K; Bergman U; Helin-Salmivaara A; Hoffmann M; Kieler H; Martikainen J; Mortensen M; Petzold M; Wallach-Kildemoes H; Wallin C; Sørensen H
    Pharmacoepidemiol Drug Saf; 2013 Jul; 22(7):691-9. PubMed ID: 23703712
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Method for the Minimization of Competition Bias in Signal Detection from Spontaneous Reporting Databases.
    Arnaud M; Salvo F; Ahmed I; Robinson P; Moore N; Bégaud B; Tubert-Bitter P; Pariente A
    Drug Saf; 2016 Mar; 39(3):251-60. PubMed ID: 26715499
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comparison of disproportionality analysis methods in national adverse drug reaction databases of China.
    Hou Y; Ye X; Wu G; Cheng G; Du X; He J
    Expert Opin Drug Saf; 2014 Jul; 13(7):853-7. PubMed ID: 24918197
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Actions in response to drug safety signals arising from a spontaneous reporting system: Retrospective study in The Netherlands.
    Rolfes L; Kolfschoten J; van Hunsel F; Kooijman M; van Puijenbroek E
    Int J Risk Saf Med; 2016 Aug; 28(2):115-23. PubMed ID: 27567768
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.